Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 09 September 2025 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees.

A total of 114’931 new SDRS have been created representing a 0.2 % increase in the total number of SDRs. The total number of outstanding SDRs has increased to 58’326’468 post issuance from 58’211’537 pre issuance.

The Annual General Meeting held on 10 May 2022 authorized the Board of Directors to execute a Long-Term Incentive Plan under which senior executives and selected key employees are rewarded share-based incentives.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer

Teleph